Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways

Journal of Virology

Volumn 75, Issue 19, 2001, Pages 9129-9141

  Fielding, C A ^a   Sandvej, K ^a   Mehl, A ^a   Brennan, P ^a   Jones, M ^a   Rowe, M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; JANUS KINASE; LATENT MEMBRANE PROTEIN 1; LUCIFERASE; STAT PROTEIN; TRANSCRIPTION FACTOR AP 1;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; ONCOGENE; PLASMID; PRIORITY JOURNAL; REPORTER GENE; SIGNAL TRANSDUCTION; VIRUS CARCINOGENESIS;

AMINO ACID SEQUENCE; HERPESVIRUS 4, HUMAN; HUMANS; JURKAT CELLS; MOLECULAR SEQUENCE DATA; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; VARIATION (GENETICS); VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

EID: 0034847766     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.19.9129-9141.2001     Document Type: Article

References (79)

1. Phosphatidylcholine hydrolysis activates NF-κB and increases human immunodeficiency virus replication in human monocytes and T lymphocytes
2. Degradation of the Epstein-Barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue
3. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus
4. Constitutive nuclear factor κB-Re1A activation is required for proliferation and survival of Hodgkin's disease tumor cells
5. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells
6. Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway
7. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75)
8. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity
9. Signal transduction through the T cell receptor-CD3 complex. Evidence for heterogeneity in receptor coupling
10. Mechanism of action of a novel latent membrane protein-1 dominant negative
11. Localization of the major NF-κB-activating site and the sole TRAF3 binding site of LMP1 defines two distinct signalling motifs
12. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors
13. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population
14. Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells
15. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-κB activation
16. Role of the TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression
17. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line
18. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains
19. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2
20. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukln-8 production
21. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors
22. Activation of the c-Jun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1)
23. Expression of the Epstein-Barr virus genome in nasopharyngeal carcinoma
24. Inducible loss of NF-κB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes
25. Functional analysis of different LMP1 proteins isolated from Epstein-Barr virus-positive carriers
26. Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C terminus functional regions
27. Epstein-Barr virus latent membrane protein-1 (LMP1) C terminus activation region 2 (CTAR2) maps to the far C terminus and requires oligomerisation for NF-κB activation
28. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
29. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule
30. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity
31. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death
32. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells
33. Involvement of two NF-κB binding elements in tumor necrosis factor alpha-, CD40-, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene
34. Differences in the immunogenicity of latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus genomes derived from LMP1-positive and -negative nasopharyngeal carcinoma
35. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and nonexpressing nasopharyngeal carcinomas
36. Clonability and tumorigenicity of human epithelial cells expressing the EBV-encoded membrane protein LMP1
37. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma
38. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxyterminal cytoplasmic domain
39. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB
40. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation
41. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-κB activation
42. The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes
43. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations
44. Epstein-Barr virus and its replication
45. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2
46. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
47. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor
48. Epstein-Barr virus latent membrane protein-1 oncogene deletions: Correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas
49. Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders
50. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma
51. Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus-negative Hodgkin's disease
52. Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB
53. CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 (EBV LMP1) via NF-κB
54. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus
55. Inhibition of in vitro proliferation of Epstein-Barr virus infected B cells by an antisense oligonucleotide targeted against EBV latent membrane protein LMP1
56. Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor κB to activate transcription
57. Novel intertypic recombinants of Epstein-Barr virus in the Chinese population
58. The NPC derived C15 LMP1 protein confers enhanced activation of NF-κB and induction of the EGFR in epithelial cells
59. Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus
60. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family
61. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease
62. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells
63. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells
64. Three pathways of Epstein-Barr virus (EBV) gene activation from EBNA1-positive latency in B lymphocytes
65. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells
66. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3
67. Latent membrane protein 1 of Epstein-Barr virus inhibits as well as stimulates gene expression
68. Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: Selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site
69. Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: Identification of four variants among wild-type EBV isolates
70. Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: High frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas
71. The Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is nonimmunogenic in a murine model system, in contrast to a B-cell-derived homologue
72. The molecular epidemiology and evolution of Epstein-Barr virus: Sequence variation and genetic recombination in the latent membrane protein-1 gene
73. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: Deletion of the amino terminus abolishes activity
74. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
75. Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines
76. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines
77. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6
78. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease
79. Epstein-Barr virus gene expression in nasopharyngeal carcinoma